Business Context and Reporting Period
This Form 8-K is a current report filed by BioXcel Therapeutics, Inc. (BTAI) on March 21, 2025, regarding events occurring on March 20, 2025. The Company is incorporated in Delaware and its common stock is registered on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The Company received a notification from Nasdaq on March 20, 2025, confirming that it failed to regain compliance with the Market Value of Listed Securities (MVLS) requirement. Specifically, the Company's MVLS remained below the minimum $35 million threshold for 30 consecutive business days prior to September 20, 2024, and failed to meet the requirement by the March 19, 2025 deadline.
Outlook, Risks, and Management Commentary
- Delisting Notice: Nasdaq has determined that the Company's securities will be delisted unless an appeal is filed.
- Appeal Process: Management intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
- Trading Status: The request for a hearing will stay further delisting action. The common stock will remain listed and eligible for trading on Nasdaq pending the outcome of the hearing.
- Risk: There is no assurance that the Company will ultimately regain compliance or remain listed on Nasdaq following the hearing process.
Investor Verification Checklist
- Verify the current market value of listed securities (MVLS) to assess the gap against the $35 million requirement.
- Monitor the status of the Company's appeal request and the scheduled hearing date with the Nasdaq Hearings Panel.
- Review the Company's capitalization and recent stock price trends to evaluate the likelihood of regaining compliance.
- Check for any subsequent filings regarding the outcome of the hearing or alternative listing strategies.